术前应用生脉注射液对老年结肠癌患者术后血管新生因子和细胞免疫功能的影响  

Influences of preoperative application of shengmai injection on angiogenesis factors and cellular immune function in elderly patients with colon cancer after operation

作　　者：赵俊 任高通 

机构地区：[1]杭州市老年病医院药剂科,浙江杭州310002 [2]慈溪人民医院药剂科,浙江宁波315300

出　　处：《中国中西医结合消化杂志》2018年第11期961-963,共3页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

基　　金：杭州市卫生计生科技计划(No:2015B51)

摘　　要：[目的]观察术前应用生脉注射液对老年结肠癌患者术后血管新生因子、细胞免疫功能的影响和安全性。[方法]收集76例老年结肠癌患者作为观察对象,回顾性分析其临床资料,按照治疗方案分为对照组和试验组,每组各38例。所有患者均接受手术治疗。术前,对照组给予常规治疗,试验组在对照组基础上给予生脉注射液50ml,1次/d,静脉滴注。比较2组患者血管内皮生长因子(VEGF)、促血管生成素1(Ang-1)血管新生因子水平、CD4+、CD8+T淋巴细胞水平、CD4+/CD8+比值及药物不良反应。[结果]术后,试验组和对照组的VEGF分别为(180.72±16.14)ng/L和(201.36±19.51)ng/L,Ang-1分别为(16.50±2.17)ng/L和(20.57±2.43)ng/L,CD4+分别为(43.82±5.86)%和(30.24±4.08)%,CD8+分别为(23.55±3.28)%和(31.45±4.53)%,CD4+/CD8+分别为(1.95±0.23)和(0.94±0.12),经检验分析显示有统计学差异(均P<0.05)。不良反应观察显示,试验组和对照组药物不良反应发生率组间比较差异无统计学意义(21.05%18.42%,P>0.05)。[结论]术前应用生脉注射液在老年结肠癌患者中效果良好,能够降低相关血管新生因子,减轻免疫功能损伤,且不良反应轻微。[Objective]To observe the influences of preoperative application of shengmai injection on angiogenesis factors,cellular immune function and safety in elderly patients with colon cancer after operation.[Methods]76 elderly patients with colon cancer were collected as observational objects.Retrospectively analyzing their clinical materials,those patients were divided into the control group and the treatment group with 38 cases in each group according to therapeutic schemes.All patients received therapy of operation.Before operation,the control group was received conventional treatment and the treatment group was treated shengmai injection 50 ml,qd,intravenous drip.Levels of angiogenesis factors of vascular endothelial growth factor(VEGF),angiopoietin 1(Ang-1),levels of CD4+,CD8+T lymphocytes,CD4+/CD8+ratio and drug adverse reactions were compared between the two groups.[Results]After operation,the main indexes in the treatment group and the control group were compared:VEGF were(180.72±16.14)ng/L and(201.36±19.51)ng/L;Ang-1 were(16.50±2.17)ng/L and(20.57±2.43)ng/L;CD4+were(43.82±5.86)%and(30.24±4.08)%;CD8+were(23.55±3.28)%and(31.45±4.53)%;CD4+/CD8+were(1.95±0.23)and(0.94±0.12),the differences were statistically significant(all P<0.05).The incidences of drug adverse reactions in the treatment group and the treatment group were 21.05%and 18.42% with no statistical difference(P>0.05).[Conclusion]Preoperative application of shengmai injection has well effect in elderly patients with colon cancer.And shengmai injection can reduce the levels of related angiogenesis factors and alleviate the damage of immune function with minor drug adverse reactions.

关 键 词：结肠癌 老年 血管新生因子 血管内皮生长因子 促血管生成素1 细胞免疫功能 

分 类 号：R735.3[医药卫生—肿瘤]